Aspira Women’s Health (NASDAQ:AWH) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Aspira Women’s Health (NASDAQ:AWH) in a research report issued on Wednesday. The brokerage set a “hold” rating on the stock.

Separately, Alliance Global Partners reduced their price objective on shares of Aspira Women’s Health from $7.00 to $5.50 and set a “buy” rating for the company in a report on Wednesday, August 14th.

Aspira Women’s Health Price Performance

Shares of Aspira Women’s Health stock opened at $0.84 on Wednesday. The business has a 50-day simple moving average of $0.86 and a 200 day simple moving average of $1.45. Aspira Women’s Health has a one year low of $0.74 and a one year high of $5.65. The firm has a market capitalization of $13.46 million, a price-to-earnings ratio of -0.58 and a beta of 1.44.

Aspira Women’s Health (NASDAQ:AWH) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.04. The firm had revenue of $2.42 million for the quarter, compared to the consensus estimate of $2.60 million. During the same quarter in the prior year, the firm earned ($0.28) EPS. On average, sell-side analysts expect that Aspira Women’s Health will post -1.26 EPS for the current year.

Hedge Funds Weigh In On Aspira Women’s Health

An institutional investor recently raised its position in Aspira Women’s Health stock. B. Riley Wealth Advisors Inc. grew its holdings in shares of Aspira Women’s Health Inc. (NASDAQ:AWH) by 88.6% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 236,396 shares of the company’s stock after purchasing an additional 111,022 shares during the quarter. B. Riley Wealth Advisors Inc. owned approximately 1.90% of Aspira Women’s Health worth $352,000 at the end of the most recent reporting period. 12.19% of the stock is currently owned by institutional investors.

Aspira Women’s Health Company Profile

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.